Â鶹´«Ã½Ó³»­

Â鶹´«Ã½Ó³»­

Explore the latest content from across our publications
Join The Â鶹´«Ã½Ó³»­

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Two-Year Interim Analysis of Thyroid Abnormalities in a Trial of Alemtuzumab vs. High-Dose Interferon Beta-1a for Treatment of Relapsing-Remitting Multiple Sclerosis
MS and Related Diseases
(-)
087
Authors/Disclosures
Alasdair Coles, MD, PhD (University of Cambridge) Dr. Coles has nothing to disclose.
No disclosure on file
Ricardo F. Allegri, MD, PhD, FÂ鶹´«Ã½Ó³»­ (Institute for Neurological Research (FLENI)) Dr. Allegri has nothing to disclose.
No disclosure on file